CD8A and neoplasm: Therefore, we further established a C57BL/6 mouse tumor model, and the results showed that, compared with the control group, the bevacizumab group had a smaller tumor volume, a higher level of infiltration of CD103+CD8+ TRMs in the tumor tissues, and a higher tumor-killing ability (Fig. 3G–K).